While the existing gene therapy was approved for use in Europe in 2024, it is very expensive, which limits its accessibility. Moreover, this treatment modifies a globin repressor gene, which indeed ...
The ROAR trial tested the hypothesis that returning familial hypercholesterolemia-associated genetic results leads to improved clinical management and outcomes in the VA system. The result was a ...
"Reprinted from the November 1929, 2nd printing, enlarged and revised October 1928" https://siris-libraries.si.edu/ipac20/ipac.jsp?&profile=liball&source ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results